Evidence map›Paper›PMID 25664170›Full record

ReviewF1000Research2014

A review of creatine supplementation in age-related diseases: more than a supplement for athletes.

Rachel N Smith, Amruta S Agharkar, Eric B Gonzales

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in F1000Research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05562232 (The Effect of Creatine Monohydrate on Persistent Post-concussive Symptoms - a Pilot Study Protocol), which is not on this map. Cited by 50 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 4 pooled it
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05562232 naunknown statusnot on this mapstarted 2023, after this paper: background citation

The Effect of Creatine Monohydrate on Persistent Post-concussive Symptoms - a Pilot Study Protocol

TypeinterventionalSponsorPsychiatric Research Unit, Region Zealand, DenmarkRan2023 to 2024Enrolled45ConditionsMild Traumatic Brain Injury, Concussion, BrainArmsCreatine Monohydrate
3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 4 syntheses or guidelines pooled it, 80 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Creatine as a Therapeutic Target in Alzheimer's Disease.Current developments in nutrition · 2023
    Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Rachel N SmithDepartment of Pharmacology & Neuroscience, UNT Health Science Center, Fort Worth, TX, TX, 76107, USA.
Amruta S AgharkarDepartment of Pharmacology & Neuroscience, UNT Health Science Center, Fort Worth, TX, TX, 76107, USA.
Eric B GonzalesDepartment of Pharmacology & Neuroscience, UNT Health Science Center, Fort Worth, TX, TX, 76107, USA ; Institute for Aging and Alzheimer's Disease Research, UNT Health Science Center, Fort Worth, TX, TX, 76107, USA ; Cardiovascular Research Institute, UNT Health Science Center, Fort Worth, TX, TX, 76107, USA.
University of North Texas · USUniversity of North Texas Health Science Center · US

Funding

Training in the Neurobiology of Aging and Alzheimer's DiseaseT32AG020494 · NIA · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI ROBERT Clinton BARBER, NATHALIE SUMIEN · 2002 to 2026
$6.9M
NIA NIH HHS T32 AG020494
6 · The paper itself

Abstract

Creatine is an endogenous compound synthesized from arginine, glycine and methionine. This dietary supplement can be acquired from food sources such as meat and fish, along with athlete supplement powders. Since the majority of creatine is stored in skeletal muscle, dietary creatine supplementation has traditionally been important for athletes and bodybuilders to increase the power, strength, and mass of the skeletal muscle. However, new uses for creatine have emerged suggesting that it may be important in preventing or delaying the onset of neurodegenerative diseases associated with aging. On average, 30% of muscle mass is lost by age 80, while muscular weakness remains a vital cause for loss of independence in the elderly population. In light of these new roles of creatine, the dietary supplement's usage has been studied to determine its efficacy in treating congestive heart failure, gyrate atrophy, insulin insensitivity, cancer, and high cholesterol. In relation to the brain, creatine has been shown to have antioxidant properties, reduce mental fatigue, protect the brain from neurotoxicity, and improve facets/components of neurological disorders like depression and bipolar disorder. The combination of these benefits has made creatine a leading candidate in the fight against age-related diseases, such as Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, long-term memory impairments associated with the progression of Alzheimer's disease, and stroke. In this review, we explore the normal mechanisms by which creatine is produced and its necessary physiology, while paying special attention to the importance of creatine supplementation in improving diseases and disorders associated with brain aging and outlining the clinical trials involving creatine to treat these diseases.

Indexed as

age-related diseasescentral nervous systemCreatine

Identifiers

PMID25664170
PMCPMC4304302
OpenAlexW2009480866

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.